Abstract
Neuropathic pain resulting from damage or dysfunction of the nervous system is a highly debilitating chronic pain state and is often resistant to currently available treatments. It has become clear that neuroinflammation, mainly mediated by proinflammatory cytokines and chemokines, plays an important role in the establishment and maintenance of neuropathic pain. Chemokines were originally identified as regulators of peripheral immune cell trafficking and were also expressed in neurons and glial cells in the central nervous system. In recent years, accumulating studies have revealed the expression, distribution and function of chemokines in the spinal cord under chronic pain conditions. In this review, we provide evidence showing that several chemokines are upregulated after peripheral nerve injury and contribute to the pathogenesis of neuropathic pain via different forms of neuron–glia interaction in the spinal cord. First, chemokine CX3CL1 is expressed in primary afferents and spinal neurons and induces microglial activation via its microglial receptor CX3CR1 (neuron-to-microglia signaling). Second, CCL2 and CXCL1 are expressed in spinal astrocytes and act on CCR2 and CXCR2 in spinal neurons to increase excitatory synaptic transmission (astrocyte-to-neuron signaling). Third, we recently identified that CXCL13 is highly upregulated in spinal neurons after spinal nerve ligation and induces spinal astrocyte activation via receptor CXCR5 (neuron-to-astrocyte signaling). Strategies that target chemokine-mediated neuron-glia interactions may lead to novel therapies for the treatment of neuropathic pain.
Similar content being viewed by others
Abbreviations
- AD:
-
Alzheimer’s disease
- AMPA:
-
Alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
- BCP:
-
Bone cancer pain
- CCI:
-
Chronic constriction injury
- CFA:
-
Complete Freund’s adjuvant
- CNS:
-
Central nervous system
- CSF:
-
Cerebrospinal fluid
- DRG:
-
Dorsal root ganglion
- EAE:
-
Experimental autoimmune encephalomyelitis
- ERK:
-
Extracellular signal-regulated kinase
- EPSC:
-
Excitatory postsynaptic currents
- GABA:
-
Gamma-aminobutyric acid
- IL:
-
Interleukin
- IAMNT:
-
Inferior alveolar nerve and mental nerve transection
- JNK:
-
c-Jun N-terminal kinase
- MAPK:
-
Mitogen-activated protein kinase
- MCP-1:
-
Monocytes chemoattractant protein-1
- MS:
-
Multiple sclerosis
- LTP:
-
Long-term potentiation
- NMDA:
-
N-methyl-d-aspartic acid
- pIONL:
-
Partial infraorbital nerve ligation
- PNS:
-
Peripheral nervous system
- pSNL:
-
Partial sciatic nerve ligation
- SNL:
-
Spinal nerve ligation
- SNI:
-
Spared nerve injury
- TNF-α:
-
Tumor necrosis factor-alpha
- TG:
-
Trigeminal ganglion
References
Baron R (2009) Neuropathic pain: a clinical perspective. Handbook of experimental pharmacology, vol 194. pp 3–30. doi:10.1007/978-3-540-79090-7_1
Gao YJ, Ji RR (2010) Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther 126 (1):56–68. doi:10.1016/j.pharmthera.2010.01.002
Ji RR, Woolf CJ (2001) Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 8(1):1–10
Ji RR, Xu ZZ, Gao YJ (2014) Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 13(7):533–548. doi:10.1038/nrd4334
Ji RR, Strichartz G (2004) Cell signaling and the genesis of neuropathic pain. Sci STKE 2004(252):reE14
Abbadie C (2005) Chemokines, chemokine receptors and pain. Trends Immunol 26(10):529–534
Sommer C, Kress M (2004) Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 361(1–3):184–187
Ji RR, Kohno T, Moore KA, Woolf CJ (2003) Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 26(12):696–705
Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, Gravel C, Salter MW, De Koninck Y (2005) BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438(7070):1017–1021
Woolf CJ, Mannion RJ (1999) Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 353(9168):1959–1964
Gao YJ, Ji RR (2010) Targeting astrocyte signaling for chronic pain. Neurother 7(4):482–493. doi:10.1016/j.nurt.2010.05.016
Aldskogius H, Kozlova EN (2013) Microglia and neuropathic pain. CNS Neurol Disord Drug Targets 12(6):768–772
Cao H, Zhang YQ (2008) Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev 32(5):972–983
Scholz J, Woolf CJ (2007) The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 10(11):1361–1368. doi:10.1038/nn1992
Ji RR, Chamessian A, Zhang YQ (2016) Pain regulation by non-neuronal cells and inflammation. Science (New York, NY) 354(6312):572–577. doi:10.1126/science.aaf8924
Tanga FY, Raghavendra V, DeLeo JA (2004) Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem Int 45(2–3):397–407. doi:10.1016/j.neuint.2003.06.002
Zhang X, Xu Y, Wang J, Zhou Q, Pu S, Jiang W, Du D (2012) The effect of intrathecal administration of glial activation inhibitors on dorsal horn BDNF overexpression and hind paw mechanical allodynia in spinal nerve ligated rats. J Neural Transm (Vienna) 119(3):329–336. doi:10.1007/s00702-011-0713-7
Ledeboer A, Sloane EM, Milligan ED, Frank MG, Mahony JH, Maier SF, Watkins LR (2005) Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115(1–2):71–83. doi:10.1016/j.pain.2005.02.009
Hayakawa K, Nakano T, Irie K, Higuchi S, Fujioka M, Orito K, Iwasaki K, Jin G, Lo EH, Mishima K, Fujiwara M (2010) Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 30(4):871–882. doi:10.1038/jcbfm.2009.257
Ji RR, Berta T, Nedergaard M (2013) Glia and pain: is chronic pain a gliopathy? Pain 154(Suppl 1):S10–S28. doi:10.1016/j.pain.2013.06.022
Gao YJ, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu ZZ, Park JY, Lind AL, Ma Q, Ji RR (2009) JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci 29(13):4096–4108
Zhang ZJ, Cao DL, Zhang X, Ji RR, Gao YJ (2013) Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. Pain 154(10):2185–2197. doi:10.1016/j.pain.2013.07.002
Biber K, Boddeke E (2014) Neuronal CC chemokines: the distinct roles of CCL21 and CCL2 in neuropathic pain. Front Cell Neurosci 8:210. doi:10.3389/fncel.2014.00210
Jiang BC, Cao DL, Zhang X, Zhang ZJ, He LN, Li CH, Zhang WW, Wu XB, Berta T, Ji RR, Gao YJ (2016) CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. J Clin Invest 126(2):745–761. doi:10.1172/JCI81950
Clark AK, Malcangio M (2014) Fractalkine/CX3CR1 signaling during neuropathic pain. Front Cell Neurosci 8:121. doi:10.3389/fncel.2014.00121
Zhang ZJ, Dong YL, Lu Y, Cao S, Zhao ZQ, Gao YJ (2012) Chemokine CCL2 and its receptor CCR2 in the medullary dorsal horn are involved in trigeminal neuropathic pain. J Neuroinflammation 9:136. doi:10.1186/1742-2094-9-136
Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White FA (2009) Chemokines and pain mechanisms. Brain Res Rev 60(1):125–134
Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354(6):610–621
Old EA, Malcangio M (2012) Chemokine mediated neuron-glia communication and aberrant signalling in neuropathic pain states. Curr Opin Pharmacol 12(1):67–73. doi:10.1016/j.coph.2011.10.015
Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18:217–242
Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A (2009) Chemokines and chemokine receptors: an overview. Front Biosci 14:540–551
Giovannelli A, Limatola C, Ragozzino D, Mileo AM, Ruggieri A, Ciotti MT, Mercanti D, Santoni A, Eusebi F (1998) CXC chemokines interleukin-8 (IL-8) and growth-related gene product alpha (GROalpha) modulate Purkinje neuron activity in mouse cerebellum. J Neuroimmunol 92(1–2):122–132
Limatola C, Giovannelli A, Maggi L, Ragozzino D, Castellani L, Ciotti MT, Vacca F, Mercanti D, Santoni A, Eusebi F (2000) SDF-1alpha-mediated modulation of synaptic transmission in rat cerebellum. Eur J Neurosci 12(7):2497–2504
Mennicken F, Maki R, de Souza EB, Quirion R (1999) Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. Trends Pharmacol Sci 20(2):73–78
Savarin-Vuaillat C, Ransohoff RM (2007) Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurother 4(4):590–601. doi:10.1016/j.nurt.2007.07.004
Ubogu EE, Cossoy MB, Ransohoff RM (2006) The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 27(1):48–55
Kim SH, Chung JM (1992) An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50(3):355–363
Decosterd I, Woolf CJ (2000) Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87(2):149–158
Bennett GJ, Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33(1):87–107
Seltzer Z, Dubner R, Shir Y (1990) A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43(2):205–218
Hu SJ, Xing JL (1998) An experimental model for chronic compression of dorsal root ganglion produced by intervertebral foramen stenosis in the rat. Pain 77(1):15–23
Milligan ED, Sloane EM, Watkins LR (2008) Glia in pathological pain: a role for fractalkine. J Neuroimmunol 198(1–2):113–120
Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC (2004) Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci 20(5):1150–1160
Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ (2000) Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci 20(15):RC87
Kim KW, Vallon-Eberhard A, Zigmond E, Farache J, Shezen E, Shakhar G, Ludwig A, Lira SA, Jung S (2011) In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood 118(22):e156–e167. doi:10.1182/blood-2011-04-348946
Lindia JA, McGowan E, Jochnowitz N, Abbadie C (2005) Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain 6(7):434–438
Schall T (1997) Fractalkine–a strange attractor in the chemokine landscape. Immunol Today 18(4):147
Hesselgesser J, Horuk R (1999) Chemokine and chemokine receptor expression in the central nervous system. J Neurovirol 5(1):13–26
Clark AK, Malcangio M (2012) Microglial signalling mechanisms: Cathepsin S and Fractalkine. Exp Neurol 234(2):283–292. doi:10.1016/j.expneurol.2011.09.012
Li D, Huang ZZ, Ling YZ, Wei JY, Cui Y, Zhang XZ, Zhu HQ, Xin WJ (2015) Up-regulation of CX3CL1 via nuclear factor-kappaB-dependent histone acetylation is involved in paclitaxel-induced peripheral neuropathy. Anesthesiology 122(5):1142–1151. doi:10.1097/ALN.0000000000000560
Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR (2007) Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun 21(5):642–651
Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102(4):1186–1195. doi:10.1182/blood-2002-12-3775
Hundhausen C, Schulte A, Schulz B, Andrzejewski MG, Schwarz N, von Hundelshausen P, Winter U, Paliga K, Reiss K, Saftig P, Weber C, Ludwig A (2007) Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 178(12):8064–8072
Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276(41):37993–38001. doi:10.1074/jbc.M106434200
Fonovic UP, Jevnikar Z, Kos J (2013) Cathepsin S generates soluble CX3CL1 (fractalkine) in vascular smooth muscle cells. Biol Chem 394(10):1349–1352. doi:10.1515/hsz-2013-0189
Clark AK, Yip PK, Grist J, Gentry C, Staniland AA, Marchand F, Dehvari M, Wotherspoon G, Winter J, Ullah J, Bevan S, Malcangio M (2007) Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci USA 104(25):10655–10660
Souza GR, Talbot J, Lotufo CM, Cunha FQ, Cunha TM, Ferreira SH (2013) Fractalkine mediates inflammatory pain through activation of satellite glial cells. Proc Natl Acad Sci USA 110(27):11193–11198. doi:10.1073/pnas.1307445110
Staniland AA, Clark AK, Wodarski R, Sasso O, Maione F, D’Acquisto F, Malcangio M (2010) Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem 114(4):1143–1157. doi:10.1111/j.1471-4159.2010.06837.x
Old EA, Nadkarni S, Grist J, Gentry C, Bevan S, Kim KW, Mogg AJ, Perretti M, Malcangio M (2014) Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain. J Clin Invest 124(5):2023–2036. doi:10.1172/JCI71389
Milligan E, Zapata V, Schoeniger D, Chacur M, Green P, Poole S, Martin D, Maier SF, Watkins LR (2005) An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur J Neurosci 22(11):2775–2782
Clark AK, Yip PK, Malcangio M (2009) The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci 29(21):6945–6954
Jin SX, Zhuang ZY, Woolf CJ, Ji RR (2003) p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 23(10):4017–4022
Gong QJ, Li YY, Xin WJ, Zang Y, Ren WJ, Wei XH, Zhang T, Liu XG (2009) ATP induces long-term potentiation of C-fiber-evoked field potentials in spinal dorsal horn: the roles of P2 × 4 receptors and p38 MAPK in microglia. Glia 57(6):583–591. doi:10.1002/glia.20786
Chu YX, Zhang Y, Zhang YQ, Zhao ZQ (2010) Involvement of microglial P2 × 7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses. Brain Behav Immun 24(7):1176–1189. doi:10.1016/j.bbi.2010.06.001
Bian C, Zhao ZQ, Zhang YQ, Lu N (2015) Involvement of CX3CL1/CX3CR1 signaling in spinal long term potentiation. PloS One 10(3):e0118842. doi:10.1371/journal.pone.0118842
Bian C, Wang ZC, Yang JL, Lu N, Zhao ZQ, Zhang YQ (2014) Up-regulation of interleukin-23 induces persistent allodynia via CX3CL1 and interleukin-18 signaling in the rat spinal cord after tetanic sciatic stimulation. Brain Behav Immun 37:220–230. doi:10.1016/j.bbi.2013.12.011
Milligan ED, Zapata V, Chacur M, Schoeniger D, Biedenkapp J, O’Connor KA, Verge GM, Chapman G, Green P, Foster AC, Naeve GS, Maier SF, Watkins LR (2004) Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci 20(9):2294–2302
Holmes FE, Arnott N, Vanderplank P, Kerr NC, Longbrake EE, Popovich PG, Imai T, Combadiere C, Murphy PM, Wynick D (2008) Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour. J Neurochem 106(2):640–649. doi:10.1111/j.1471-4159.2008.05419.x
White FA, Jung H, Miller RJ (2007) Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA 104(51):20151–20158
Jung H, Bhangoo S, Banisadr G, Freitag C, Ren D, White FA, Miller RJ (2009) Visualization of chemokine receptor activation in transgenic mice reveals peripheral activation of CCR2 receptors in states of neuropathic pain. J Neurosci 29(25):8051–8062
Gosselin RD, Dansereau MA, Pohl M, Kitabgi P, Beaudet N, Sarret P, Melik Parsadaniantz S (2008) Chemokine network in the nervous system: a new target for pain relief. Curr Med Chem 15(27):2866–2875
Kurihara T, Bravo R (1996) Cloning and functional expression of mCCR2, a murine receptor for the C–C chemokines JE and FIC. J Biol Chem 271(20):11603–11607
Imai S, Ikegami D, Yamashita A, Shimizu T, Narita M, Niikura K, Furuya M, Kobayashi Y, Miyashita K, Okutsu D, Kato A, Nakamura A, Araki A, Omi K, Nakamura M, James Okano H, Okano H, Ando T, Takeshima H, Ushijima T, Kuzumaki N, Suzuki T (2013) Epigenetic transcriptional activation of monocyte chemotactic protein 3 contributes to long-lasting neuropathic pain. Brain 136(Pt 3):828–843. doi:10.1093/brain/aws330
Dansereau MA, Gosselin RD, Pohl M, Pommier B, Mechighel P, Mauborgne A, Rostene W, Kitabgi P, Beaudet N, Sarret P, Melik-Parsadaniantz S (2008) Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J Neurochem 106(2):757–769. doi:10.1111/j.1471-4159.2008.05429.x
Tanaka T, Minami M, Nakagawa T, Satoh M (2004) Enhanced production of monocyte chemoattractant protein-1 in the dorsal root ganglia in a rat model of neuropathic pain: possible involvement in the development of neuropathic pain. Neurosci Res 48(4):463–469
Jung H, Toth PT, White FA, Miller RJ (2008) Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J Neurochem 104(1):254–263
White FA, Sun J, Waters SM, Ma C, Ren D, Ripsch M, Steflik J, Cortright DN, Lamotte RH, Miller RJ (2005) Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci USA 102(39):14092–14097
Zhang J, De Koninck Y (2006) Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem 97(3):772–783
Zhang J, Shi XQ, Echeverry S, Mogil JS, De Koninck Y, Rivest S (2007) Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci 27(45):12396–12406
Miller RJ, Jung H, Bhangoo SK, White FA (2009) Cytokine and chemokine regulation of sensory neuron function. Handbook of experimental pharmacology, vol 194. pp 417–449. doi:10.1007/978-3-540-79090-7_12
Van Steenwinckel J, Reaux-Le Goazigo A, Pommier B, Mauborgne A, Dansereau MA, Kitabgi P, Sarret P, Pohl M, Melik Parsadaniantz S (2011) CCL2 released from neuronal synaptic vesicles in the spinal cord is a major mediator of local inflammation and pain after peripheral nerve injury. J Neurosci 31(15):5865–5875. doi:10.1523/JNEUROSCI.5986-10.2011
Luo W, Fu R, Tan Y, Fang B, Yang Z (2014) Chemokine CCL2 up-regulated in the medullary dorsal horn astrocytes contributes to nocifensive behaviors induced by experimental tooth movement. Eur J Oral Sci 122(1):27–35. doi:10.1111/eos.12099
Tanuma N, Sakuma H, Sasaki A, Matsumoto Y (2006) Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol 112(2):195–204
Yan YP, Sailor KA, Lang BT, Park SW, Vemuganti R, Dempsey RJ (2007) Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. J Cereb Blood Flow Metab 27(6):1213–1224
Babcock AA, Kuziel WA, Rivest S, Owens T (2003) Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 23(21):7922–7930
Abbadie C, Lindia JA, Cumiskey AM, Peterson LB, Mudgett JS, Bayne EK, DeMartino JA, MacIntyre DE, Forrest MJ (2003) Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci USA 100(13):7947–7952
Moreno M, Bannerman P, Ma J, Guo F, Miers L, Soulika AM, Pleasure D (2014) Conditional ablation of astroglial CCL2 suppresses CNS accumulation of M1 macrophages and preserves axons in mice with MOG peptide EAE. J Neurosci 34(24):8175–8185. doi:10.1523/JNEUROSCI.1137-14.2014
Thacker MA, Clark AK, Bishop T, Grist J, Yip PK, Moon LD, Thompson SW, Marchand F, McMahon SB (2009) CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain 13(3):263–272
Ji RR, Baba H, Brenner GJ, Woolf CJ (1999) Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 2(12):1114–1119
Gao YJ, Ji RR (2009) c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury? Open Pain J 2:11–17
Gosselin RD, Varela C, Banisadr G, Mechighel P, Rostene W, Kitabgi P, Melik-Parsadaniantz S (2005) Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurones. J Neurochem 95(4):1023–1034
Menetski J, Mistry S, Lu M, Mudgett JS, Ransohoff RM, Demartino JA, Macintyre DE, Abbadie C (2007) Mice overexpressing chemokine ligand 2 (CCL2) in astrocytes display enhanced nociceptive responses. Neuroscience 149(3):706–714
Begin-Lavallee V, Midavaine E, Dansereau MA, Tetreault P, Longpre JM, Jacobi AM, Rose SD, Behlke MA, Beaudet N, Sarret P (2016) Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development. Mol Pain. doi:10.1177/1744806916653969
Verri WA Jr, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH (2006) Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther 112(1):116–138. doi:10.1016/j.pharmthera.2006.04.001
Cunha TM, Verri WA Jr, Schivo IR, Napimoga MH, Parada CA, Poole S, Teixeira MM, Ferreira SH, Cunha FQ (2008) Crucial role of neutrophils in the development of mechanical inflammatory hypernociception. J Leukoc Biol 83(4):824–832. doi:10.1189/jlb.0907654
Carreira EU, Carregaro V, Teixeira MM, Moriconi A, Aramini A, Verri WA Jr, Ferreira SH, Cunha FQ, Cunha TM (2013) Neutrophils recruited by CXCR1/2 signalling mediate post-incisional pain. Eur J Pain 17(5):654–663. doi:10.1002/j.1532-2149.2012.00240.x
Valles A, Grijpink-Ongering L, de Bree FM, Tuinstra T, Ronken E (2006) Differential regulation of the CXCR2 chemokine network in rat brain trauma: implications for neuroimmune interactions and neuronal survival. Neurobiol Dis 22(2):312–322. doi:10.1016/j.nbd.2005.11.015
Popivanova BK, Koike K, Tonchev AB, Ishida Y, Kondo T, Ogawa S, Mukaida N, Inoue M, Yamashima T (2003) Accumulation of microglial cells expressing ELR motif-positive CXC chemokines and their receptor CXCR2 in monkey hippocampus after ischemia-reperfusion. Brain Res 970(1–2):195–204
Nguyen D, Stangel M (2001) Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. Brain Res Dev Brain Res 128(1):77–81
Manjavachi MN, Costa R, Quintao NL, Calixto JB (2014) The role of keratinocyte-derived chemokine (KC) on hyperalgesia caused by peripheral nerve injury in mice. Neuropharmacology 79:17–27. doi:10.1016/j.neuropharm.2013.10.026
Pineau I, Sun L, Bastien D, Lacroix S (2010) Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. Brain Behav Immun 24(4):540–553. doi:10.1016/j.bbi.2009.11.007
Xu J, Zhu MD, Zhang X, Tian H, Zhang JH, Wu XB, Gao YJ (2014) NFkappaB-mediated CXCL1 production in spinal cord astrocytes contributes to the maintenance of bone cancer pain in mice. J Neuroinflammation 11:38. doi:10.1186/1742-2094-11-38
Omari KM, John G, Lango R, Raine CS (2006) Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 53(1):24–31. doi:10.1002/glia.20246
Chen G, Park CK, Xie RG, Berta T, Nedergaard M, Ji RR (2014) Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice. Brain 137(Pt 8):2193–2209. doi:10.1093/brain/awu140
Cao DL, Zhang ZJ, Xie RG, Jiang BC, Ji RR, Gao YJ (2014) Chemokine CXCL1 enhances inflammatory pain and increases NMDA receptor activity and COX-2 expression in spinal cord neurons via activation of CXCR2. Exp Neurol 261:328–336. doi:10.1016/j.expneurol.2014.05.014
Yang LH, Xu GM, Wang Y (2016) Up-regulation of CXCL1 and CXCR2 contributes to remifentanil-induced hypernociception via modulating spinal NMDA receptor expression and phosphorylation in rats. Neurosci Lett 626:135–141. doi:10.1016/j.neulet.2015.12.044
Sun Y, Sahbaie P, Liang DY, Li WW, Li XQ, Shi XY, Clark JD (2013) Epigenetic regulation of spinal CXCR2 signaling in incisional hypersensitivity in mice. Anesthesiology 119(5):1198–1208. doi:10.1097/ALN.0b013e31829ce340
Manjavachi MN, Quintao NL, Campos MM, Deschamps IK, Yunes RA, Nunes RJ, Leal PC, Calixto JB (2010) The effects of the selective and non-peptide CXCR2 receptor antagonist SB225002 on acute and long-lasting models of nociception in mice. Eur J Pain 14(1):23–31. doi:10.1016/j.ejpain.2009.01.007
Lin CP, Kang KH, Lin TH, Wu MY, Liou HC, Chuang WJ, Sun WZ, Fu WM (2015) Role of spinal CXCL1 (GROalpha) in opioid tolerance: a human-to-rodent translational study. Anesthesiology 122(3):666–676. doi:10.1097/ALN.0000000000000523
Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD, Browning JL, Lipp M, Cyster JG (2000) A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406(6793):309–314. doi:10.1038/35018581
Katayama T, Tanaka H, Yoshida T, Uehara T, Minami M (2009) Neuronal injury induces cytokine-induced neutrophil chemoattractant-1 (CINC-1) production in astrocytes. J Pharmacol Sci 109(1):88–93
Kim CH, Rott LS, Clark-Lewis I, Campbell DJ, Wu L, Butcher EC (2001) Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med 193(12):1373–1381
Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, Hofbauer M, Farina C, Derfuss T, Hartle C, Newcombe J, Hohlfeld R, Meinl E (2006) Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129(Pt 1):200–211. doi:10.1093/brain/awh680
Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT (1998) A B-cell-homing chemokine made in lymphoid follicles activates Burkitt’s lymphoma receptor-1. Nature 391(6669):799–803. doi:10.1038/35876
Bagaeva LV, Rao P, Powers JM, Segal BM (2006) CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis. J Immunol 176(12):7676–7685
Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F (2004) Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 148(1–2):11–23. doi:10.1016/j.jneuroim.2003.10.056
Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT (2003) Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101(3):815–821. doi:10.1182/blood-2002-05-1576
Wallace VC, Cottrell DF, Brophy PJ, Fleetwood-Walker SM (2003) Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids. J Neurosci 23(8):3221–3233
Ljostad U, Mygland A (2008) CSF B–lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. J Neurol 255(5):732–737. doi:10.1007/s00415-008-0785-y
Polomano RC, Mannes AJ, Clark US, Bennett GJ (2001) A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94(3):293–304
Rainey-Barger EK, Rumble JM, Lalor SJ, Esen N, Segal BM, Irani DN (2011) The lymphoid chemokine, CXCL13, is dispensable for the initial recruitment of B cells to the acutely inflamed central nervous system. Brain Behav Immun 25(5):922–931. doi:10.1016/j.bbi.2010.10.002
Zhang Q, Cao DL, Zhang ZJ, Jiang BC, Gao YJ (2016) Chemokine CXCL13 mediates orofacial neuropathic pain via CXCR5/ERK pathway in the trigeminal ganglion of mice. J Neuroinflammation 13(1):183. doi:10.1186/s12974-016-0652-1
Strong JA, Xie W, Coyle DE, Zhang JM (2012) Microarray analysis of rat sensory ganglia after local inflammation implicates novel cytokines in pain. PloS One 7(7):e40779. doi:10.1371/journal.pone.0040779
Zhang Q, Zhu MD, Cao DL, Bai XQ, Gao YJ, Wu XB (2017) Chemokine CXCL13 activates p38 MAPK in the trigeminal ganglion after infraorbital nerve injury. Inflammation. doi:10.1007/s10753-017-0520-x
Jiang BC, He LN, Wu XB, Shi H, Zhang WW, Zhang ZJ, Cao DL, Li CH, Gu J, Gao YJ (2017) Promoted Interaction of C/EBPalpha with Demethylated Cxcr3 gene promoter contributes to neuropathic pain in mice. J Neurosci 37(3):685–700. doi:10.1523/JNEUROSCI.2262-16.2017
Guan XH, Fu QC, Shi D, Bu HL, Song ZP, Xiong BR, Shu B, Xiang HB, Xu B, Manyande A, Cao F, Tian YK (2015) Activation of spinal chemokine receptor CXCR3 mediates bone cancer pain through an Akt-ERK crosstalk pathway in rats. Exp Neurol 263:39–49. doi:10.1016/j.expneurol.2014.09.019
Luo X, Tai WL, Sun L, Pan Z, Xia Z, Chung SK, Cheung CW (2016) Crosstalk between astrocytic CXCL12 and microglial CXCR4 contributes to the development of neuropathic pain. Mol Pain. doi:10.1177/1744806916636385
Hu XM, Liu YN, Zhang HL, Cao SB, Zhang T, Chen LP, Shen W (2015) CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer rats. J Neurochem 132(4):452–463. doi:10.1111/jnc.12985
Shen W, Hu XM, Liu YN, Han Y, Chen LP, Wang CC, Song C (2014) CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord. J Neuroinflammation 11:75. doi:10.1186/1742-2094-11-75
Bai L, Wang X, Li Z, Kong C, Zhao Y, Qian JL, Kan Q, Zhang W, Xu JT (2016) Upregulation of chemokine CXCL12 in the dorsal root ganglia and spinal cord contributes to the development and maintenance of neuropathic pain following spared nerve injury in rats. Neurosci Bull 32(1):27–40. doi:10.1007/s12264-015-0007-4
Knerlich-Lukoschus F, von der Ropp-Brenner B, Lucius R, Mehdorn HM, Held-Feindt J (2011) Spatiotemporal CCR1, CCL3(MIP-1alpha), CXCR4, CXCL12(SDF-1alpha) expression patterns in a rat spinal cord injury model of posttraumatic neuropathic pain. J Neurosurg Spine 14(5):583–597. doi:10.3171/2010.12.SPINE10480
Luo X, Tai WL, Sun L, Qiu Q, Xia Z, Chung SK, Cheung CW (2014) Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice. PloS One 9(8):e104860. doi:10.1371/journal.pone.0104860
Xie F, Wang Y, Li X, Chao YC, Yue Y (2016) Early repeated administration of CXCR4 antagonist AMD3100 dose-dependently improves neuropathic pain in rats after L5 spinal nerve ligation. Neurochem Res 41(9):2289–2299. doi:10.1007/s11064-016-1943-8
de Jong EK, Vinet J, Stanulovic VS, Meijer M, Wesseling E, Sjollema K, Boddeke HW, Biber K (2008) Expression, transport, and axonal sorting of neuronal CCL21 in large dense-core vesicles. Faseb J 22(12):4136–4145. doi:10.1096/fj.07-101907
Dijkstra IM, de Haas AH, Brouwer N, Boddeke HW, Biber K (2006) Challenge with innate and protein antigens induces CCR7 expression by microglia in vitro and in vivo. Glia 54(8):861–872. doi:10.1002/glia.20426
Biber K, Tsuda M, Tozaki-Saitoh H, Tsukamoto K, Toyomitsu E, Masuda T, Boddeke H, Inoue K (2011) Neuronal CCL21 up-regulates microglia P2 × 4 expression and initiates neuropathic pain development. EMBO J 30(9):1864–1873. doi:10.1038/emboj.2011.89
Kiguchi N, Kobayashi Y, Kishioka S (2012) Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol 12(1):55–61. doi:10.1016/j.coph.2011.10.007
Kiguchi N, Kobayashi Y, Maeda T, Saika F, Kishioka S (2010) CC-chemokine MIP-1alpha in the spinal cord contributes to nerve injury-induced neuropathic pain. Neurosci Lett 484(1):17–21. doi:10.1016/j.neulet.2010.07.085
Padi SS, Shi XQ, Zhao YQ, Ruff MR, Baichoo N, Pert CB, Zhang J (2012) Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2- and CCR5-mediated monocyte chemotaxis and inflammation. Pain 153(1):95–106. doi:10.1016/j.pain.2011.09.022
Horuk R (2009) Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 8(1):23–33. doi:10.1038/nrd2734
Pease JE, Horuk R (2009) Chemokine receptor antagonists: Part 1. Expert Opin Ther Pat 19(1):39–58. doi:10.1517/13543770802641346
Pease JE, Horuk R (2009) Chemokine receptor antagonists: part 2. Expert Opin Ther Pat 19(2):199–221. doi:10.1517/13543770802641353
Pease JE, Horuk R (2014) Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4. Expert Opin Drug Discov 9(5):467–483. doi:10.1517/17460441.2014.897324
Pease J, Horuk R (2012) Chemokine receptor antagonists. J Med Chem 55(22):9363–9392. doi:10.1021/jm300682j
Kalliomaki J, Attal N, Jonzon B, Bach FW, Huizar K, Ratcliffe S, Eriksson B, Janecki M, Danilov A, Bouhassira D (2013) A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain 154(5):761–767. doi:10.1016/j.pain.2013.02.003
Acknowledgements
This study was supported by the grants from the National Natural Science Foundation of China (NSFC 31371121, 81400915, 81571070, and 31671091), the National Science Foundation for Young Scientists of Jiangsu Province (BK20140427), the Qing Lan Project, and the Priority Academic Program Development of Jiangsu Higher Education Institutions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Zhang, ZJ., Jiang, BC. & Gao, YJ. Chemokines in neuron–glial cell interaction and pathogenesis of neuropathic pain. Cell. Mol. Life Sci. 74, 3275–3291 (2017). https://doi.org/10.1007/s00018-017-2513-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-017-2513-1